Ensoma has a total of 20 patents globally. Of these 20 patents, more than 80% patents are active. United States of America seems to be the main focused R&D centre and also is the origin country of Ensoma.
Ensoma was founded in 2019. Ensoma is a biotechnology company. The company offers diagnostic services and specializes in genomic medications for gene therapy, hematology, oncology, and uncommon disease treatment.
Do read about some of the most popular patents of Ensoma which have been covered by us in this article and also you can find Ensoma patents information, the worldwide patent filing activity and its patent filing trend over the years, and many other stats over Ensoma patent portfolio.
How many patents does Ensoma have?
Ensoma has a total of 20 patents globally. These patents belong to 5 unique patent families. Out of 20 patents, 16 patents are active.
How Many Patents did Ensoma File Every Year?
Are you wondering why there is a drop in patent filing for the last two years? It is because a patent application can take up to 18 months to get published. Certainly, it doesn’t suggest a decrease in the patent filing.
| Year of Patents Filing or Grant | Ensoma Applications Filed | Ensoma Patents Granted |
| 2023 | 4 | – |
| 2022 | 4 | – |
| 2021 | 12 | – |
How many Ensoma patents are Alive/Dead?
Worldwide Patents
How Many Patents did Ensoma File in Different Countries?
Countries in which Ensoma Filed Patents
| Country | Patent |
| Argentina | 3 |
| Taiwan | 3 |
| Israel | 2 |
| Australia | 2 |
| Brazil | 2 |
| Canada | 2 |
| Indonesia | 1 |
Where are Research Centers of Ensoma Patents Located?
The Research Centers of Ensoma Patents is the United States of America.
List of Ensoma patents
| Ensoma Patents | Title |
| WO2023150393A3 | Inhibitor-Resistant Mgmt Modifications And Modification Of Mgmt-Encoding Nucleic Acids |
| CA3204988A1 | Adenoviral Serotype 35 Helper Vectors |
| CA3204826A1 | Adenoviral Gene Therapy Vectors |
| AU2021410006A1 | Adenoviral Serotype 35 Helper Vectors |
| AU2021410765A1 | Adenoviral Gene Therapy Vectors |
| IL303899A | Adenoviral Gene Therapy Vectors |
| IL303901A | Adenoviral Serotype 35 Helper Vectors |
| AR125368A1 | Adenoviral Vectors For Gene Therapy |
| TW202304527A | Adenoviral Gene Therapy Vectors |
| AR126031A1 | Adenoviral Auxiliary Vectors Of Serotype 35 |
| AR124489A1 | Adenoviral Vectors For Genotherapy |
| ID202307211A | Adenovirus Serotype 35 Helping Vector |
| TW202242119A | Adenoviral Serotype 35 Helper Vectors |
| TW202242123A | Adenoviral Gene Therapy Vectors |
| BR112023012465A2 | Adenoviral Auxiliary Vectors Serotype 35 |
| BR112023012461A2 | Adenoviral Vectors For Gene Therapy |
| WO2022216877A1 | Modification Of Epor-Encoding Nucleic Acids |
| WO2022221702A3 | Adenoviral Gene Therapy Vectors |
| WO2022140605A3 | Adenoviral Serotype 35 Helper Vectors |
| WO2022140618A8 | Adenoviral Gene Therapy Vectors |
What are Ensoma key innovation segments?
What Technologies are Covered by Ensoma?
The chart below distributes patents filed by Ensoma